Valuation: Laboratorio Reig Jofre SA

Market Cap 21Cr 24Cr 20Cr 18Cr 34Cr 2.33TCr 35Cr 235.07Cr 92Cr 1.15TCr 92Cr 90Cr 3.94TCr P/E 2026 *
13.1x
P/E 2027 * 21.8x
Enterprise Value 30Cr 34Cr 27Cr 25Cr 48Cr 3.25TCr 49Cr 328.42Cr 128.97Cr 1.6TCr 127.92Cr 125.13Cr 5.5TCr EV / Sales 2026 *
0.82x
EV / Sales 2027 * 0.75x
Free-Float
20.57%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 58 01/01/2006
Director of Finance/CFO - 20/12/2023
Chief Tech/Sci/R&D Officer - 01/01/2003
Director TitleAgeSince
Director/Board Member 58 31/12/2014
Director/Board Member - 31/12/2014
Director/Board Member - 31/12/2014
Change 5-day change 1-year change 3-year change Capi.($)
-2.33%-2.09%+49.88%+170.51% 1,06000Cr
-0.82%-2.30%+63.79%+62.00% 62TCr
-0.73%-4.98%+28.91%+82.99% 44TCr
+0.33%-1.17%+31.07%+27.09% 33TCr
-0.02%-2.85%+29.15%+45.24% 28TCr
-3.89%-11.22%+22.81%+27.30% 27TCr
+0.66%-1.42%-26.59%-37.71% 22TCr
-0.06%-2.88%+23.07%+62.33% 20TCr
-3.72%-1.10%+18.41%+70.56% 16TCr
Average -1.18%-3.25%+26.72%+56.70% 39.71TCr
Weighted average by Cap. -1.31%-2.96%+36.75%+83.91%

Financials

2026 *2027 *
Net sales 36Cr 42Cr 34Cr 31Cr 59Cr 3.98TCr 60Cr 402.15Cr 157.92Cr 1.96TCr 156.64Cr 153.23Cr 6.74TCr 39Cr 45Cr 36Cr 33Cr 63Cr 4.27TCr 64Cr 431.9Cr 169.61Cr 2.11TCr 168.23Cr 164.56Cr 7.24TCr
Net income 1.67Cr 1.91Cr 1.54Cr 1.42Cr 2.7Cr 182.09Cr 2.74Cr 18Cr 7.23Cr 90Cr 7.17Cr 7.01Cr 308.38Cr 95L 1.09Cr 87.63L 80.93L 1.54Cr 103.58Cr 1.56Cr 10Cr 4.11Cr 51Cr 4.08Cr 3.99Cr 175.43Cr
Net Debt 8.47Cr 9.68Cr 7.81Cr 7.22Cr 14Cr 923.54Cr 14Cr 93Cr 37Cr 454.96Cr 36Cr 36Cr 1.56TCr 7.87Cr 9Cr 7.26Cr 6.7Cr 13Cr 858.12Cr 13Cr 87Cr 34Cr 422.74Cr 34Cr 33Cr 1.45TCr
Logo Laboratorio Reig Jofre SA
Laboratorio Reig Jofre SA, formerly Natraceutical SA, is a Spain-based company primarily engaged in the research, development, manufacturing and marketing of drugs. The Company’s activities are divided into four business divisions: Industrial Services, providing production services for third parties; Pharma, selling own pharmaceuticals under a range of brands, such as Reig Jofre, Medea, Orravan, Bioglan and Sala; Reaserch and Development (R&D) and Regulatory, including the development of indications for existing molecules, as well as generics and molecular diagnostics, among others; and Biotech, offering biopharmaceutical support services, such as analytical and process development, quality control and assurance, as well as stability studies. The Company also provides nutritional cosmetics, and food supplements, among others. It operates worldwide in Europe, Africa, the Americas, Australia and Asia through a number of subsidiaries, including Chiesi Espana SA and Oryzon Genomics SA.
Employees
-
Trader
-
Investor
Global
-
Quality
ESG MSCI
-